ClinicalTrials.gg
RecruitingNCT05095090CHESTYUpdated Oct 6, 2026

Study of Hospitalised Patients With Acute Respiratory Conditions

An observational study in Acute Respiratory Disease, COPD Exacerbation Acute and Asthma, sponsored by University of Leicester. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of Leicester · Observational

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.
Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 558 studies in Asthma with a site in United Kingdom — 52 open to participants now, 71 under way, 11 of them phase 3. Asthma · United Kingdom.

Planned enrollment
35th of 131
500 · median 149
Started
2022
with 25 others
Observational
131 of 558
24 open now
Primary completion
2029-10
later than 63 of 70 live
Registered
442nd of 558
by date

Among the 558 studies in Asthma with a site in United Kingdom, this one is the 35th largest by planned enrollment of the 131 observational ones that give a count, is one of 26 that started in 2022, is one of 131 observational ones, reaches primary completion later than 63 of the 70 other live ones, and was the 442nd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

52 of the 558 studies in Asthma with a site in United Kingdom are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 558 studies in Asthma with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the short- and long-term outcomes of people admitted to hospital with an acute respiratory condition, including exacerbations of chronic lung disease, and to understand factors that may predict recovery, hospital readmission, length of hospital stay, and mortality. A group of people with chronic respiratory disease who are being followed in respiratory outpatient clinics and a healthy control group without lung disease will also take part.

The main questions it aims to answer are:

  • Which clinical, physical, functional, and biological characteristics are associated with short-term outcomes after hospitalisation, including 30-day hospital readmission, length of hospital stay, and 30-day mortality?
  • Which characteristics are associated with longer-term recovery, future exacerbations, hospital readmissions, healthcare use, and mortality?
  • Can measurements taken during or around the time of hospitalisation be used to identify people at greater risk of poor outcomes who may benefit from targeted interventions?

Participants will undergo clinical assessments that may include questionnaires, measurements of physical function and muscle strength, lung function tests, physical activity monitoring, and collection of biological samples. Some participants may also undergo additional assessments of body composition, muscle size and function, imaging, or muscle metabolism, including through nested sub-studies. Participants will be followed for up to 36 months to assess recovery and longer-term clinical outcomes.

Read the detailed description

The study will recruit adults who are either admitted to hospital with an acute respiratory condition or are under the care of hospital respiratory outpatient services for a chronic respiratory disease. Acute respiratory presentations may include exacerbations of chronic lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, bronchiectasis and pleural disease, as well as acute respiratory illnesses including pneumonia, respiratory infection and pulmonary embolism. A separate healthy control group without underlying respiratory disease will also be recruited for comparison of selected exploratory measures.

Participants may be recruited during hospital admission or through respiratory outpatient services. Baseline assessments will be completed during hospitalisation or within 90 days of a routine clinical follow-up appointment, depending on the route of recruitment.

Participants recruited during an acute hospital admission may be invited to complete an early post-discharge assessment at approximately 30 days and up to three additional optional follow-up visits during the 12 months after discharge to assess clinical recovery. Participants recruited through respiratory outpatient services will be invited to undergo annual follow-up assessments. Follow-up for the main cohort will continue for up to 36 months, with permitted visit windows of up to 90 days.

Follow-up assessments may be completed by telephone, during a face-to-face research visit at the Biomedical Research Centre, during a research visit for another ethically approved study, or alongside routine clinical follow-up. Participants may choose not to attend further study visits after recruitment without affecting their usual clinical care.

If a participant is admitted to hospital during study follow-up, they may be invited to complete an additional assessment during the acute admission, within 7 days of hospitalisation, followed by up to three further assessments during the subsequent 12 months. Healthcare utilisation and clinical outcome data, including subsequent hospital admissions and treatments, may also be collected remotely from primary and secondary healthcare records.

Study assessments may include clinical characteristics, symptoms, health-related quality of life, frailty, sarcopenia, physical function, muscle strength, lung function, physical activity, body composition, muscle structure and function, physiological measurements, imaging and biological samples. These data will be used to characterise recovery following acute respiratory illness, investigate hospital-associated disability, explore potential biomarkers and develop approaches to risk stratification.

Healthy controls will undergo a baseline assessment only and will provide comparator data for selected exploratory outcomes.

MPES SUB-STUDY:

The Muscle Phenotyping Exploratory Study (MPES) is a sub-study nested within CHESTY and will be conducted at Glenfield Hospital. It is designed to provide more detailed assessment of skeletal muscle structure, function and metabolism using methods that complement the broader clinical phenotyping undertaken in the main CHESTY cohort.

The sub-study has two main aims. First, it will assess the feasibility, safety and tolerability of the additional muscle phenotyping methods, including high-density surface electromyography (EMG), ingested stable isotope tracer methodology and muscle biopsy procedures, in participants with respiratory disease and healthy volunteers. Second, it will use these methods exploratorily to undertake detailed skeletal muscle phenotyping, including assessment of muscle activation and neuromuscular function, skeletal muscle mass, muscle protein synthesis and muscle protein breakdown.

Up to 20 participants will be recruited to each of three groups: patients hospitalised with an acute exacerbation of COPD, patients with stable COPD, and age-comparable control participants without chronic respiratory disease. Participants may be recruited from existing CHESTY participants who have provided appropriate consent or through the same screening and recruitment pathways used for the main CHESTY study.

The MPES sub-study will use the same study site, research team and core assessments as CHESTY, including measures of physical function and muscle strength, questionnaires and muscle biopsy procedures where applicable.

03

Conditions studied

  • Acute Respiratory Disease
  • COPD Exacerbation Acute
  • Asthma
  • Pneumonia

Keywords

  • Asthma
  • COPD (Chronic Obstructive Pulmonary Disease)
  • Pneumonia
  • ILD (Interstitial Lung Diseases)
  • Pulmonary Embolism
  • Pleural Diseases
  • Bronchiectasis
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Participants will include adults admitted to hospital with an acute respiratory condition, including exacerbations of an underlying physician-diagnosed chronic respiratory disease, as well as non-hospitalised patients under respiratory outpatient follow-up for a chronic respiratory condition. The study will also include healthy volunteers without chronic respiratory disease as a comparator group. Co-participation in other ethically approved studies, including interventional trials, is permitted.

Eligibility criteria

Inclusion Criteria (Core study participants)

  1. Hospital admission with an acute respiratory diagnosis, or currently under the care of hospital respiratory outpatient services for a chronic respiratory disease
  2. Participant is willing \& able to give for participation in the study
  3. Aged 18 years or above
  4. Able (in the Investigators opinion) \& willing to comply with all study requirements

Exclusion Criteria (Core study participants)

  1. Unstable or life-threatening cardiac disease including myocardial infarction or unstable angina during current admission.
  2. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  3. Known pregnancy

Inclusion Criteria (Healthy Controls)

  1. Aged 18 years or above
  2. No underlying respiratory disease as self-reported
  3. Able (in the Investigators opinion) \& willing to comply with all study requirements

Exclusion Criteria (Healthy Controls)

  1. Hospitalised due to an acute respiratory illness in the last 6 weeks prior to consent
  2. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  3. Known pregnancy

Additional inclusion and exclusion criteria for CHESTY sub-studies are detailed in the corresponding sub-study protocols.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Hospitalised Patients

    Participants admitted to hospital with an acute respiratory condition including exacerbation of an underlying physician diagnosed chronic lung disease.

  • Matched Controls (stable COPD and healthy volunteers)

    The study will include matched controls (non-hospitalised patients with stable chronic respiratory conditions or healthy volunteers) to compare the exploratory endpoints. The number of the matched controls will not exceed 25% of the main study recruitment.

06

What researchers measure

Primary outcomes

  1. 30 days hospital re-admission rate

    To calculate the percentage of readmission due to the same acute respiratory illness within 30 days from consent

    Time frame: 30 days

  2. Length of index hospital admission stay

    To calculate the length of the index hospital stay

    Time frame: Variable (up to 52 weeks)

  3. 30 days mortality rate

    To calculate the percentage of mortality within 30 days from consent

    Time frame: 30 days

Secondary outcomes

  1. Total number of hospital readmission due to same underlying chronic lung disease.

    To evaluate the number of hospital readmission episodes due to same underlying chronic lung disease over a 52 weeks period.

    Time frame: 52 weeks

  2. Total number of non-hospitalised exacerbations of underlying chronic lung disease

    To evaluate the number of non-hospitalised exacerbations of chronic lung disease e.g. asthma, Chronic Obstructive Pulmonary Diseases (COPD), etc. over 52 weeks

    Time frame: 52 weeks

  3. Time from consent to death (respiratory causes and all causes)

    To measure the time from consent to death within 52 weeks from consent. This will include both respiratory and all causes of mortality

    Time frame: 52 weeks

Other outcomes

  1. Assessment of breathlessness using eMRC dyspnoea scale

    To evaluate the degree of breathlessness at baseline and following recovery from acute respiratory illness using Extended MRC dyspnoea scale(eMRC). eMRC dyspnoea scale ranges from 1 to 5b with higher score indicates worse outcomes.

    Time frame: 52 weeks

  2. Assessment of quality of Life/symptoms using St. George's Respiratory Questionnaire (SGRQ)

    St. George's Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Oct 2029, 92 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 92 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2021
First posted
Oct 27, 2021
StartActual
Feb 2, 2022
Primary completionEst.
Oct 31, 2029
CompletionEst.
Oct 30, 2033
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05095090
Collaborators
University Hospitals, Leicester
Responsible party
Sponsor
First posted
Oct 27, 2021
Start date
Feb 2, 2022
Primary completion
Oct 31, 2029 (estimated)
Completion
Oct 30, 2033 (estimated)
Last update
Oct 6, 2026

Study contacts

Jill Clanchy
Contact
chesty-catalina@leicester.ac.uk
+44 (0)116 258 3370
Hamish McAuley, MBBS, MRCP
Contact
hjcm1@leicester.ac.uk
Neil Greening, PhD, MRCP
principal investigator · NIHR Respiratory Biomedical Research Centre, Leicester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion